Autoinflammatory & rare systemic diseases
bDMARD can prevent the progression of AA amyloidosis (AA) amyloidosis to end-stage renal disease
Authors' conclusion
bDMARDs reduce systemic inflammation in various diseases, leading to a reduction of proteinuria and prevention of ESRD. Importantly, tocilizumab was more effective than other bDMARDs in controlling systemic inflammation in patients with chronic inflammatory diseases and idiopathic AA, leading to better renal and overall survival.
Study context
- Population
- Patients with renal AA amyloidosis treated with cytokine-inhibiting biological disease-modifying antirheumatic drugs (bDMARDs), single centremean follow-up 4.82 years
- Participants
- 83 patients
- Exposure
- Renal outcome with cytokine-inhibiting bDMARDs across AA amyloidosis subtypes; tocilizumab vs other bDMARDs
- cid+AAn = 34
- auto+AAn = 24
- idio+AAn = 25
- Outcome
- Renal outcome (progression to ESRD) and survival
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
Progression to ESRD prevented
Observational data: associations, not effects.
Further findings
C reactive protein (CRP), serum amyloid alpha and proteinuria with bDMARD therapy
- Significantly reduced with bDMARD therapy
Tocilizumab (n=34, cid+AA and idio+AA) vs other bDMARDs
- Tocilizumab more effective in reducing CRP and progression to end-stage renal disease (ESRD) and death compared with other bDMARDs
Original publication
bDMARD can prevent the progression of AA amyloidosis to end-stage renal disease. Ann Rheum Dis. Published 27 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →